and they're gonna spend it:

an understandable move considering the ambitious list of actions that WuXi is ready to spend on, spelled out in their application:

Expansion of capacity and capabilities across all business units globally, including seven projects in China, a bioanalytical lab in San Diego, a manufacturing plant in the US, and a Hong Kong-based R&D center
Acquisition of CRO and CMO/CDMO companies
Investing and incubating companies in biotech, healthcare IT, hospital, diagnostics, and tools and instruments
Developing cutting-edge technology such as AI-empowered drug discovery platform

https://endpts.com/wuxi-apptec-files-for-publ...nghai-ipo/